Disclosures for "End-of-Life Care in Neurodegenerative Diseases: Assessment and Perspectives for Community Pharmacist Involvement"
-
Dr. Auffret has received personal compensation for serving as an employee of France Développement Electronique. Dr. Auffret has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aguettant. The institution of Dr. Auffret has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aguettant. The institution of Dr. Auffret has received research support from Oxylis Medical. Dr. Auffret has received publishing royalties from a publication relating to health care. Dr. Auffret has received publishing royalties from a publication relating to health care. Dr. Auffret has received publishing royalties from a publication relating to health care. Dr. Auffret has received publishing royalties from a publication relating to health care.
-
Mrs. Conty has nothing to disclose.
-
Dr. Keromnes has nothing to disclose.
-
Mr. Verin has nothing to disclose.